<DOC>
	<DOC>NCT01608555</DOC>
	<brief_summary>The study will include 10 adult patients with cystic fibrosis. The aim of the study is to evaluate whether Tobramycin 300 mg aerosol once-a-day for 28 days can reduce the bacterial load in the airways. Secondary end-point is the evaluation of variation in bacterial susceptibility during and at the end of study period.</brief_summary>
	<brief_title>Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis</brief_title>
	<detailed_description>Ten adult patients with cystic fibrosis will be enrolled in a stable phase and will received prophylaxis with aerosol of Tobramycin 300 mg once a day for 28 days.</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Outpatients, male and female, age range 1845 years Diagnosis of cystic fibrosis FEV1 &gt;50% predicted. sputum samples available Chest x ray negative for pneumonia and tuberculosis Informed consent Allergy to tobramycin Use of systemic steroids in the previous 2 weeks Pregnancy or breast feeding Treatment with other experimental drug in the previous 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>bacterial load</keyword>
	<keyword>inhaled tobramycin</keyword>
</DOC>